Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Dec
02
Today In Oncology
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
Outcomes Associated With Consensus Molecular Subtypes in First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury
Lung Cancer Screening Criteria NELSON vs PLCOm2012
ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo